Apellis Pharmaceuticals, Inc. (APLS) reported $178.49 million in revenue for the quarter ended June 2025, representing a year-over-year decline of 10.6%. EPS of -$0.33 for the same period compares to -$0.28 a year ago.
The reported revenue represents a surprise of -6.35% over the Zacks Consensus Estimate of $190.59 million. With the consensus EPS estimate being -$0.44, the EPS surprise was +25%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Apellis Pharmaceuticals performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Product revenue, net: $171.39 million versus the 10-analyst average estimate of $176.3 million. The reported number represents a year-over-year change of -4.3%.
- Revenue- Licensing and other revenue: $7.11 million versus the 10-analyst average estimate of $12.89 million. The reported number represents a year-over-year change of -65.4%.
- Product Revenue- EMPAVELI: $20.8 million versus the seven-analyst average estimate of $21.74 million. The reported number represents a year-over-year change of -15.1%.
- Product Revenue- SYFOVRE: $150.6 million versus the seven-analyst average estimate of $153.77 million. The reported number represents a year-over-year change of -2.6%.
View all Key Company Metrics for Apellis Pharmaceuticals here>>>
Shares of Apellis Pharmaceuticals have returned +6.6% over the past month versus the Zacks S&P 500 composite's +2.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Apellis Pharmaceuticals, Inc. (APLS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
